Drug Profile
HMPL 011
Alternative Names: HMPL-011Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Hutchison MediPharma
- Class Anti-inflammatories; Antirheumatics; Small molecules
- Mechanism of Action Interleukin 10 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 09 Jun 2021 Hutchison MediPharma has been acquired and merged into HUTCHMED
- 16 Jul 2016 No recent reports of development identified for phase-I development in Autoimmune-disorders(In volunteers) in Australia (PO)
- 11 Nov 2010 Pharmacodynamics data from a preclinical trial in Rheumatoid arthritis presented at the 74th Annual Scientific Meeting of the American College of Rheumatology and the 45th Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP-2010)